Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary EndpointBusiness Wire • 05/23/25
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025Zacks Investment Research • 05/09/25
Prothena Reports First Quarter 2025 Financial Results and Business HighlightsBusiness Wire • 05/08/25
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business HighlightsBusiness Wire • 02/20/25
Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law FirmGlobeNewsWire • 02/17/25
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025Business Wire • 02/13/25
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's DiseaseInvestors Business Daily • 12/19/24
Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's DiseaseBusiness Wire • 12/19/24
Prothena Reports Third Quarter 2024 Financial Results and Business HighlightsBusiness Wire • 11/12/24
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 10/29/24
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?Zacks Investment Research • 10/29/24